Who are atazanavir/raltegravir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): darunavir/ritonavir QD + raltegravir BID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atazanavir-raltegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

atazanavir/raltegravir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

atazanavir/raltegravir (atazanavir/raltegravir) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + integrase inhibitor). Area: Infectious Disease.

marketed Antiretroviral combination (protease inhibitor + integrase inhibitor) HIV protease and HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

atazanavir/raltegravir (atazanavir/raltegravir) — Community Research Initiative of New England. This combination blocks HIV protease and integrase enzymes to prevent viral replication and reduce viral load in HIV-infected patients.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
atazanavir/raltegravir TARGET	atazanavir/raltegravir	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + integrase inhibitor)	HIV protease and HIV integrase
darunavir/ritonavir QD + raltegravir BID	darunavir/ritonavir QD + raltegravir BID	ANRS, Emerging Infectious Diseases	phase 3	Protease inhibitor and integrase strand transfer inhibitor	HIV protease and HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + integrase inhibitor) class)

Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). atazanavir/raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/atazanavir-raltegravir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab